MALIGNANT PLEURAL MESOTHELIOMA
Clinical trials for MALIGNANT PLEURAL MESOTHELIOMA explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT PLEURAL MESOTHELIOMA trials appear
Sign up with your email to follow new studies for MALIGNANT PLEURAL MESOTHELIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo before surgery shows promise for mesothelioma patients
Disease control OngoingThis study tests whether giving the immunotherapy drug nivolumab along with standard chemotherapy before surgery is safe and works well for people with a type of lung cancer called malignant pleural mesothelioma. About 22 adults whose cancer can be removed by surgery will receive…
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
5-Day radiation blast targets mesothelioma after surgery
Disease control OngoingThis study tests a new way to give radiation therapy to people with malignant pleural mesothelioma, a rare and serious lung cancer. The treatment is given over just 5 days using a special machine called Tomotherapy. The goal is to see if this short, intense radiation is safe and …
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: NA • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
Promising combo targets tough lung cancer
Disease control OngoingThis early-phase study tests whether combining a special radiation therapy (IMPRINT) with the immunotherapy drug pembrolizumab is safe for people with malignant pleural mesothelioma, a rare and aggressive lung cancer. Seven participants who have already tried at least one other t…
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:39 UTC